UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder

Biological psychiatry (1969), 2010-07, Vol.68 (2), p.156-162

2010

Volltextzugriff (PDF)

Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic

The American journal of psychiatry, 2003-06, Vol.160 (6), p.1125-1132

2003

Volltextzugriff (PDF)

An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia

Child and adolescent psychiatry and mental health, 2012-06, Vol.6 (1), p.23-23, Article 23

2012

Volltextzugriff (PDF)

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial

JAMA neurology, 2021-03, Vol.78 (3), p.293

2021

Volltextzugriff (PDF)

Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases

Current drug safety, 2011-02, Vol.6 (1), p.43

2011

Volltextzugriff (PDF)

A Randomized Withdrawal, Placebo-Controlled Study Evaluating the Efficacy and Tolerability of Tapentadol Extended Release in Patients With Chronic Painful Diabetic Peripheral Neuropathy

Diabetes care, 2014-08, Vol.37 (8), p.2302-2309

2014

Volltextzugriff (PDF)

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder

British journal of psychiatry, 2007-08, Vol.191 (2), p.131-139

2007

Volltextzugriff (PDF)

Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study

Journal of autism and developmental disorders, 2013-08, Vol.43 (8), p.1773-1783

2013

Volltextzugriff (PDF)

Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study

Neurology, 2024-01, Vol.102 (2), p.e207937

2024

Volltextzugriff (PDF)

Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain

Pain physician, 2014-07, Vol.17 (4), p.329-343

2014

Volltextzugriff (PDF)

Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients

British journal of psychiatry, 2016-11, Vol.209 (5), p.378-384

2016

Volltextzugriff (PDF)

An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder

Journal of child and adolescent psychopharmacology, 2013-12, Vol.23 (10), p.676

2013

Volltextzugriff (PDF)

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open-label study

British journal of psychiatry, 2007-08, Vol.191 (2), p.131-139

2007

Volltextzugriff (PDF)

Rapid Antimanic Effect of Risperidone Monotherapy: A 3-Week Multicenter, Double-Blind, Placebo-Controlled Trial

The American journal of psychiatry, 2004-06, Vol.161 (6), p.1057-1065

2004

Volltextzugriff (PDF)

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic

The journal of clinical psychiatry, 2003-10, Vol.64 (10), p.1250

2003

Volltextzugriff (PDF)

Risk of Cardiovascular Morbidity With Risperidone or Paliperidone Treatment: Analysis of 64 Randomized, Double-Blind Trials

Journal of clinical psychopharmacology, 2013-04, Vol.33 (2), p.157-161

2013

Volltextzugriff (PDF)

FTS3‐01‐04: FINAL EFFICACY, SAFETY AND BIOMARKER RESULTS OF THE PHASE 2B/3 RANDOMIZED, DOUBLE‐BLINDED, PLACEBO‐CONTROLLED EARLY TRIAL OF ATABECESTAT IN PRECLINICAL ALZHEIMER'S DISEASE

Alzheimer's & dementia, 2019-07, Vol.15 (7S_Part_17), p.P873-P874

2019

Volltextzugriff (PDF)

FINAL EFFICACY, SAFETY AND BIOMARKER RESULTS OF THE PHASE 2B/3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED EARLY TRIAL OF ATABECESTAT IN PRECLINICAL ALZHEIMER’S DISEASE

Alzheimer's & dementia, 2019-07, Vol.15 (7), p.P873-P874

2019

Volltextzugriff (PDF)

Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol

European neuropsychopharmacology, 2005, Vol.15 (1), p.75-84

2005

Volltextzugriff (PDF)

Tapentadol immediate-release for acute postbunionectomy pain: a phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan

Current medical research and opinion, 2015-11, Vol.31 (11), p.2001-2009

2015

Volltextzugriff (PDF)

Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents

Journal of child and adolescent psychopharmacology, 2008-08, Vol.18 (4), p.337

2008

Volltextzugriff (PDF)

Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions

Journal of allergy and clinical immunology, 1999-04, Vol.103 (4), p.574-580

1999

Volltextzugriff (PDF)

Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder: Vascular Function in Depression in Older Adults

Biological psychiatry (1969), 2010, Vol.68 (2), p.156-162

2010

Volltextzugriff (PDF)

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controled, open-label study

British journal of psychiatry, 2007-08, Vol.191, p.131-139

2007

Volltextzugriff (PDF)

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder : Randomised, controlled, open-label study

British journal of psychiatry, 2007, Vol.191 (AOUT), p.131-139

2007

Volltextzugriff (PDF)

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(40)

Sprache

Englisch
(40)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(23)
Humans
(22)
Life Sciences & Biomedicine
(22)
Female
(17)
Male
(17)
Double-Blind Method
(12)
Psychiatry
(12)
Adult
(11)
Middle Aged
(11)
Biological And Medical Sciences
(10)
Medical Sciences
(10)
Risperidone
(10)
Treatment Outcome
(10)
Pharmacology. Drug Treatments
(9)
Risperidone - Adverse Effects
(9)
Adolescent
(8)
Neuropharmacology
(8)
Risperidone - Administration & Dosage
(8)
Antipsychotic Agents - Therapeutic Use
(7)
Psychology. Psychoanalysis. Psychiatry
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder

Long-Acting Injectable Risperidone: Efficacy and Safety of the First Long-Acting Atypical Antipsychotic

An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial

Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases

A Randomized Withdrawal, Placebo-Controlled Study Evaluating the Efficacy and Tolerability of Tapentadol Extended Release in Patients With Chronic Painful Diabetic Peripheral Neuropathy

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder

Risperidone Dosing in Children and Adolescents with Autistic Disorder: A Double-Blind, Placebo-Controlled Study

Safety and Efficacy of Nipocalimab in Patients With Generalized Myasthenia Gravis: Results From the Randomized Phase 2 Vivacity-MG Study

Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain

Baseline characteristics and treatment-emergent risk factors associated with cerebrovascular event and death with risperidone in dementia patients

An open-label extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controlled, open-label study

Rapid Antimanic Effect of Risperidone Monotherapy: A 3-Week Multicenter, Double-Blind, Placebo-Controlled Trial

Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic

Risk of Cardiovascular Morbidity With Risperidone or Paliperidone Treatment: Analysis of 64 Randomized, Double-Blind Trials

FTS3‐01‐04: FINAL EFFICACY, SAFETY AND BIOMARKER RESULTS OF THE PHASE 2B/3 RANDOMIZED, DOUBLE‐BLINDED, PLACEBO‐CONTROLLED EARLY TRIAL OF ATABECESTAT IN PRECLINICAL ALZHEIMER'S DISEASE

FINAL EFFICACY, SAFETY AND BIOMARKER RESULTS OF THE PHASE 2B/3 RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED EARLY TRIAL OF ATABECESTAT IN PRECLINICAL ALZHEIMER’S DISEASE

Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol

Tapentadol immediate-release for acute postbunionectomy pain: a phase 3, randomized, double-blind, placebo-controlled, parallel-group study in Taiwan

Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents

Onset and duration of action of levocabastine nasal spray in atopic patients under nasal challenge conditions

Risperidone Long-Acting Injectable Monotherapy in the Maintenance Treatment of Bipolar I Disorder: Vascular Function in Depression in Older Adults

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder: Randomised, controled, open-label study

Long-acting injectable risperidone v. olanzapine tablets for schizophrenia or schizoaffective disorder : Randomised, controlled, open-label study

Suchergebnisse filtern